Albany Molecular Research Inc v Arrow Pharmaceuticals Pty Ltd

Link copied
Case Copied 6 min read

FEDERAL COURT OF AUSTRALIA

Albany Molecular Research Inc v Arrow Pharmaceuticals Pty Ltd [2011] FCA 252

Citation: Albany Molecular Research Inc v Arrow Pharmaceuticals Pty Ltd [2011] FCA 252
Parties: ALBANY MOLECULAR RESEARCH, INC  v ARROW PHARMACEUTICALS PTY LTD (ACN 003 144 170), SIGMA PHARMACEUTICALS LIMITED (ACN 088 417 403), SIGMA PHARMACEUTICALS (AUSTRALIA) PTY LTD (ACN 004 118 594), SIGMA COMPANY LIMITED (ACN 004 132 923) and AVENTIS PHARMACEUTICALS, INC
File number: VID 883 of 2007
Judge: JESSUP J
Date of judgment: 23 March 2011
Legislation: Patents Act 1990 (Cth) s 138
Cases cited: Albany Molecular Research Inc v Alphapharm Pty Ltd [2011] FCA 120
Date of last submissions: 11 March 2011
Place: Melbourne
Division: GENERAL DIVISION
Category: No Catchwords
Number of paragraphs: 6
Counsel for the Applicant: Mr A Archibald QC with Mr A Ryan SC and Ms K Beattie
Solicitor for the Applicant: Phillips Ormonde Fitzpatrick
Counsel for the Respondents:  Mr D Shavin QC wth Ms H Rofe
Solicitor for the Respondents: Corrs Chambers Westgarth

IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

GENERAL DIVISION

VID883 of 2007

BETWEEN:

ALBANY MOLECULAR RESEARCH INC
Applicant/First Cross-Respondent

AVENTIS PHARMACEUTICALS, INC
Second Cross-Respondent

AND:

ARROW PHARMACEUTICALS PTY LTD (ACN 003 144 170)
First Respondent/First Cross-Claimant

SIGMA PHARMACEUTICALS LIMITED (ACN 088 417 403)
Third Respondent/Third Cross-Claimant

SIGMA PHARMACEUTICALS (AUSTRALIA) PTY LTD (ACN 004 118 594)
Fourth Respondent/Fourth Cross-Claimant

SIGMA COMPANY LIMITED (ACN 004 132 923)
Fifth Respondent/Fifth Cross-Claimant

JUDGE:

JESSUP J

DATE OF ORDER:

23 MARCH 2011

WHERE MADE:

MELBOURNE

THE COURT ORDERS THAT:

1.The application be dismissed.

THE COURT DECLARES THAT:

2.So far as it relates to Claims 1, 6, 7, 8, 9 and 10, Australian patent No 699799 is invalid.

THE COURT FURTHER ORDERS THAT:

3.So far as it relates to Claims 1, 6, 7, 8, 9 and 10, Australian patent No 699799 be revoked.

4.Upon the applicant by its counsel undertaking –

(a)       to prosecute any appeal expeditiously;

(b)during the period of the stay, not to threaten any person with proceedings for infringement of claims 1, 6, 7, 8, 9 or 10 of the said patent; and

(c)during the period of the stay, not to seek to amend any claims of the said patent otherwise than in the course of or in connection with this proceeding;

the operation of Order 3 above be stayed –

(i)for 28 days; and

(ii)if the applicant has within that 28‑day period, lodged an appeal against the making of that order, until the hearing and determination thereof or further order.

5.The cross-claim otherwise be dismissed.

6.The parties file and serve their written submissions on costs as follows:

(a)       the respondents/cross-claimants, within seven days;

(b)the applicant/cross-respondents, within a further seven days;

(c)the respondents/cross-claimants in reply (if required), within a further seven days.

Note:Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
The text of entered orders can be located using Federal Law Search on the Court’s website.


IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

GENERAL…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Albany Molecular Research Inc v Arrow Pharmaceuticals Pty Lt... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2011] FCA 252
Decision Date

CaseChat Overview and Summary

Albany Molecular Research Inc, an American corporation, initiated legal proceedings against Arrow Pharmaceuticals Pty Ltd, an Australian company, concerning the validity and infringement of Australian Patent No 699799. Albany claimed that Arrow had infringed their patent rights related to a pharmaceutical compound, while Arrow argued for the patent's invalidity and sought a declaration to that effect. The matter was heard in the Federal Court of Australia.

The primary legal issues that the court had to resolve included whether certain claims in the patent were valid and whether Arrow had infringed those claims. Specifically, the court had to determine the scope and validity of claims 1, 6, 7, 8, 9, and 10 of the patent. The court also had to consider the cross-claim brought by Arrow for a declaration of invalidity and any costs associated with the proceedings.

After thorough examination of the evidence and arguments presented by both parties, the court found that claims 1, 6, 7, 8, 9, and 10 of the patent were invalid due to issues of obviousness and lack of novelty. Consequently, the court declared these claims invalid and ordered the revocation of the patent in relation to those claims. However, the court stayed the operation of the revocation order for 28 days, and further if an appeal was lodged within that period, until the appeal was heard and determined, provided that certain conditions were met by Albany. These conditions included prosecuting any appeal expeditiously, refraining from threatening infringement proceedings during the stay period, and not seeking to amend the patent claims outside the scope of the current proceedings. The court dismissed the cross-claim brought by Arrow. Finally, the court directed the parties to submit written costs submissions within specified timeframes.

Orders

Orders of the court

1. The application be dismissed.

THE COURT DECLARES THAT:

2. So far as it relates to Claims 1, 6, 7, 8, 9 and 10, Australian patent No 699799 is invalid.

THE COURT FURTHER ORDERS THAT:

3. So far as it relates to Claims 1, 6, 7, 8, 9 and 10, Australian patent No 699799 be revoked.

4. Upon the applicant by its counsel undertaking –

(a) to prosecute any appeal expeditiously;

(b) during the period of the stay, not to threaten any person with proceedings for infringement of claims 1, 6, 7, 8, 9 or 10 of the said patent; and

(c) during the period of the stay, not to seek to amend any claims of the said patent otherwise than in the course of or in connection with this proceeding;

the operation of Order 3 above be stayed –

(i) for 28 days; and

(ii) if the applicant has within that 28‑day period, lodged an appeal against the making of that order, until the hearing and determination thereof or further order.

5. The cross-claim otherwise be dismissed.

6. The parties file and serve their written submissions on costs as follows:

(a) the respondents/cross-claimants, within seven days;

(b) the applicant/cross-respondents, within a further seven days;

(c) the respondents/cross-claimants in reply (if required), within a further seven days.

Note:

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.